Healthcare and Medical/

Non-Small Cell Lung Cancer Treatment Market Scope with Strategic Growth and Top Players Outlook 2029

Emma Anderson

Non-Small Cell Lung Cancer Treatment Market Scope with Strategic Growth and Top Players Outlook 2029

Research Nester released a report titled “Non-Small Cell Lung Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook 2029″ which delivers detailed overview of the global non-small cell lung cancer treatment market in terms of market segmentation by treatment type, end-user, and region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The non-small cell lung cancer treatment market is projected to grow with a high CAGR during the forecast period, i.e., 2021-2029 on account of the increasing prevalence of non-small cell lung cancer and rising awareness about the disease. According to World Health Organization, in 2020, there were around 2.21 million new cases and 1.80 million deaths from lung cancer globally.

The market is segmented by treatment type into surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. Among these segments, the targeted therapy segment is anticipated to hold the largest share by the end of 2021 in the non-small cell lung cancer treatment market as a result of the higher rates of adoption of targeted therapy than other available treatments. It is also gaining worldwide recognition for its usage as an adjuvant therapy with chemotherapy.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the non-small cell lung cancer treatment market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative non-small cell lung cancer treatment procedures.

Increasing Prevalence of Non-Small Cell Lung Cancer and Rising Awareness about the Disease to Drive Market Growth

Non-small cell lung cancer is the most commonly occurring forms of lung cancer. The increasing prevalence of non-small lung cancer has led to the increase in demand for non-small lung cancer therapeutics. Additionally, the rising awareness about non-small cell lung cancer in recent years is also expected to boost the market growth in upcoming years.

However, the limited treatment options for non-small lung cancer and lack of awareness about the disease in lower economic regions are some of the factors that are estimated to restrain market growth in the near future.

This report also provides the existing competitive scenario of some of the key players of the global non-small cell lung cancer treatment market which includes company profiling of Genentech, Inc., Celgene Corporation (Bristol Myers Squibb), AstraZeneca plc (LON: AZN), Elli Lilly & Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Sanofi (EPA: SAN), Astellas Pharma Inc. (TYO), Novartis AG (SWX: NOVN), Takeda Oncology, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments.

On the whole, the report depicts detailed overview of the global non-small cell lung cancer treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Emma Anderson

Non-Small Cell Lung Cancer Treatment Market Is Estimated To Witness High Growth Owing To Increasing Incidence of Lung Cancer

Anjali CMI 2023-10-10

The global non-small cell lung cancer (NSCLC) treatment market is estimated to be valued at US$ 24,910. PEST Analysis: Political: The political landscape can significantly impact the non-small cell lung cancer treatment market. Technological: Technological advancements have a significant impact on the non-small cell lung cancer treatment market. Regionally, North America is expected to be the fastest-growing and dominating region in the non-small cell lung cancer treatment market. In conclusion, the non-small cell lung cancer treatment market is projected to experience substantial growth in the coming years.

Non-Small Cell Lung Cancer Treatment Market: Rising Incidence of Lung Cancer Drives Market Growth

Sneha 2023-09-13

The global Non-Small Cell Lung Cancer Treatment Market is estimated to be valued at US$24,910. The need for effective treatment options is underscored by the increasing incidence of lung cancer, which drives the demand for non-small cell lung cancer treatments in the market. Bargaining Power of Buyers: The bargaining power of buyers in the non-small cell lung cancer treatment market is moderate. Competitive Rivalry: The non-small cell lung cancer treatment market is highly competitive, with several key players vying for market share. In conclusion, the global non-small cell lung cancer treatment market is expected to experience significant growth in the coming years.

Non-Small Cell Lung Cancer Market: Rising Incidence and Advanced Treatment Approaches

Vaishnavi Kashid 2023-07-25

The Non-Small Cell Lung Cancer (NSCLC) Market is a critical segment within the field of oncology, dedicated to addressing one of the most prevalent and deadly forms of lung cancer. According to Coherent Market Insights, Global Non-Small Cell Lung Cancer Treatment Market is estimated to be valued at US$ 24,910. Ongoing research and clinical trials are expected to drive the development of novel therapies and treatment approaches. Additionally, collaborations between industry stakeholders and advancements in technology are likely to shape the future of NSCLC treatment. As medical science continues to advance, and as personalized treatment options become more accessible, the NSCLC Market remains at the forefront of the quest for improved patient outcomes and a brighter future in the battle against lung cancer.

Global Non-small Cell Lung Cancer Market Report, Latest Trends, Industry Opportunity & Forecast to 2030

Samyukta 2023-10-28

COVID-19 Impact Analysis on Non-small Cell Lung Cancer Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2022-2030. Get more information on "Global Non-small Cell Lung Cancer Market Research Report" by requesting FREE Sample Copy at https://www. Additionally, these tools also give an inclusive assessment of each segment in the global market of non-small cell lung cancer. Browse Global Non-small Cell Lung Cancer Market Research Report with detailed TOC at https://www. Purchase Complete Global Non-small Cell Lung Cancer Market Research Report at https://www.

Non-Small Cell Lung Cancer Treatment Is Fastest Growing Segment Fueling Growth Of Non-Small Cell Lung Cancer Market

Pooja Khodke 2023-12-01

The global Non-Small Cell Lung Cancer Market is estimated to be valued at Us$ 27252. The increasing focus on precision medicines is expected to drive the non-small cell lung cancer market during the forecast period. Segment Analysis The global non-small cell lung cancer market is segmented type, treatment, end-user and region. Based on type, the non-small cell lung cancer market is segmented into squamous cell carcinoma, large cell carcinoma and adenocarcinoma. received FDA approval for Keytruda, an immuno-oncology drug for the treatment of non-small cell lung cancer.

Non-Small Cell Lung Cancer Market Size & Business Planning, Innovation to See Modest Growth Through 2026

Elena Smith 2020-02-12

Non-Small Cell Lung Cancer market OverviewNon-Small Cell Lung Cancer Market Report offers an industry-wide analysis of the market, including precise assessment of the demand for the Non-Small Cell Lung Cancer Market and accurate market insights that allow readers to identify the existing opportunities and threats and optimize their investments.

It offers the global sector across key regional markets and gives an extensive investigation and statistical analysis of vital market elements.

The study also performs an elaborate industry-wide competitive analysis, highlighting the major companies in the Non-Small Cell Lung Cancer Market that regulate a substantial portion of the global market share and infers beneficial prospects and hurdles to help the reader invest wisely.It also includes an extensive investigation on Non-Small Cell Lung Cancer manufacturers, the expansion strategies adopted by the companies to capitalize on the existing growth prospects, the financial standing, and the individual market share of the leading participants, providing the readers a comprehensive overview of the competitive scenario.To get a PDF Sample Copy (including TOC, Table of content, and facts and figures) of the Non-Small Cell Lung Cancer market report, visit@ https://www.reportsanddata.com/sample-enquiry-form/1475The following manufacturers have been studied in this report by assessing the sales, gross revenue, and market share for each company:Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.The information relating to the Non-Small Cell Lung Cancer market that has been collected and analyzed in the report will allow a brand engaged in the sector to get the upper hand against leading players in the global landscape.

This report offers insights into the competitive scenario in the market.

It also delivers a progressive perspective relating to different market aspects driving or curtailing the growth of the market.Histology Outlook (Revenue, USD Billion; 2016-2026)Squamous Cell CarcinomaLarge Cell CarcinomaAdenocarcinomaTreatment Outlook (Revenue, USD Billion; 2016-2026)SurgeryRadiationChemotherapyTargeted Therapy DrugsDrug Class Outlook (Revenue, USD Billion; 2016-2026)Angiogenesis InhibitorEpidermal Growth Factor Receptor BlockerKinase InhibitorMicrotubule StabilizerFolate AntimetabolitesPD-1/ PD-L1 InhibitorTo inquire about report customization & check for availability of incredible discount rates on this report, visit@ https://www.reportsanddata.com/discount-enquiry-form/1475The report will offer a clear view of each and every fact relating to the industry, rendering it unnecessary to refer to any other source of information or a data source.

Our report will deliver all details relating to the historical development, existing scenario, and accurate insights into the Non-Small Cell Lung Cancer Market.Regional Landscape Analysis for Non-Small Cell Lung Cancer Market:North America (United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.

WHO TO FOLLOW

MORE FROM AUTHOR

Electronic Manufacturing Software Market Overview Till 2027

Emma Anderson 2023-08-08

IoT Operating System Market Trends Analysis Till 2027

Emma Anderson 2023-08-07

LATAM Software-as-a-Service (SaaS) Market Analysis Till 2026

Emma Anderson 2023-08-04

Crowd Management and Event Security Market Opportunities 2035

Emma Anderson 2023-08-03

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.

Press enter to search

Non-Small Cell Lung Cancer Market 2023 to 2033: Advanced R&D Process Strategies

Ganesh Shinde 2023-03-02

The global non-small cell lung cancer market had a market value of US$ 10 billion in 2023 and is predicted to reach a market value of US$ 20 billion by 2033, growing at a CAGR of 7. The two primary causes of non-small cell lung cancer are excessive tobacco intake and active participation in passive smoking. Long-term air pollution exposure promotes the development of non-small cell lung cancer. Because of the prevalence of advanced healthcare infrastructure, greater research and development capabilities by pharmaceutical firms, and quick adoption of new and better healthcare technology, North America leads the non-small cell lung cancer market. com/reports/non-small-cell-lung-cancer-marketKey Segments Profiled in the Non-Small Cell Lung Cancer Market Industry SurveyNon-Small Cell Lung Cancer Market by Cancer Type:Squamous Cell CarcinomaAdenocarcinomaLarge-cell CarcinomaNon-Small Cell Lung Cancer Market by Treatment:ChemotherapyTargeted TherapyImmunotherapy

Global Small Cell Lung Cancer Therapeutics Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

saikiran TBRC 2024-04-01

Overview and ScopeSmall cell lung cancer (SCLC) is a type of lung cancer that primarily originates in the bronchi, the airways of the lungs. Small-cell Lung cancer therapeutics provide various medical approaches, treatments and interventions to manage and treat small-cell lung cancer. The small cell lung cancer therapeutics market size is expected to see rapid growth in the next few years. Treatment for lung cancer, including small cell lung cancer, usually involves a combination of chemotherapy, radiation therapy and, in some cases, targeted therapies that provide prolonged survival and improved quality of life for lung cancer patients. Therefore, the rise in the prevalence of lung cancer is driving the growth of the small-cell lung cancer therapeutics market.

Multidisciplinary Approach to Non-Small Cell Lung Cancer Management

Larry Paige 2023-07-05

A multidisciplinary approach to non-small cell lung cancer (NSCLC) management involves a collaborative effort among different healthcare professionals from various specialties. This approach recognizes that NSCLC is a complex disease that requires comprehensive and integrated care. The multidisciplinary team typically includes medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and other specialists as needed. Furthermore, the multidisciplinary team plays a vital role in monitoring treatment response, managing side effects, and providing supportive care throughout the patient's journey. The multidisciplinary approach to non-small cell lung cancer management ensures that patients receive well-coordinated, evidence-based care, maximizing the chances of successful outcomes.

Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies

Ankit Nigam 2020-10-23

According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.

The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.

Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.

Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.

Non-Small Cell Lung Cancer Market Size, Growth, Sales Revenue, Comprehensive Research Study, Demand, Growth | Industry Forecast to 2028

Chetan Khachne 2021-10-14

The Global Non-Small Cell Lung Cancer Market size is forecast to reach USD 11.87 Billion by 2028, registering a CAGR of 6.2% over the forecast period, according to a new report by Reports and Data.

Non small cell lung cancer accounts for 80 percent to 85 percent of all lung cancer cases across the world, and this high proportion has prompted the majority of market leaders to focus on constant innovation of new therapies and improving the efficacy of existing medicines.

The expansion of the non small cell lung cancer market is further aided by an increase in the frequency of diagnosis of non small cell lung cancer and increased awareness about the disease in developed and emerging countries.

This, combined with increased spending by leading companies in research and development operations, as well as the inclusion of non-small cell cancer therapies in major market participants' pipelines, is fueling global market expansion.One of the challenges of the non-small cell lung cancer market is the high cost of treatment.

Surgery performed at an early stage is the best chance to cure non small cell lung cancer.· Among the various drug class segments of the market, angiogenesis inhibitor accounted for the largest market share in 2020.

Development of public healthcare centers and subsidized treatment will fuel the market growth.Top Companies Profiled in the Report Include:Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1475Market Overview:The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness.

Non-Small Cell Lung Cancer: Understanding the Most Common Form of Lung Cancer

ashwinicmi 2024-03-13

The most advanced stage, stage IV Non-Small Cell Lung Cancer involves cancer that has metastasized or spread to other organs such as the brain, bones, liver, or other distant lymph nodes. Types of Non-Small Cell Lung Cancer There are three main types of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma makes up about 40% of lung cancer cases and usually occurs in outer parts of the lung. Large cell carcinoma comprises about 10-15% of lung cancer cases and can occur in any part of the lung. Get more insights on This Topic- Non-Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC) Therapeutics Market 2022 Size, Dynamics & Forecast Report to 2030

Vishakha Gome 2023-05-26

The global Small Cell Lung Cancer (SCLC) Therapeutics Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2022-2030. Get more information on "Global Small Cell Lung Cancer (SCLC) Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www. The growth and trends of small cell lung cancer (sclc) therapeutics industry provide a holistic approach to this study. Browse Global Small Cell Lung Cancer (SCLC) Therapeutics Market Research Report with detailed TOC at https://www. Purchase Complete Global Small Cell Lung Cancer (SCLC) Therapeutics Market Research Report at https://www.

Lung Cancer Treatment Market Analysis, Revenue Share, Company Profiles & Forecast Till 2032

David 2023-09-18

Global Lung Cancer Treatment Market size will grow substantially during 2023-2032. As per the WHO, ambient air pollution is projected to lead to 16% of lung cancer deaths, while air pollution may be responsible for around 29% of the deaths caused by lung cancer globally. com/request-sample/detail/5708The overall lung cancer treatment market is segmented based on type, therapy, end-user, and region. In terms of therapy, the lung cancer treatment market value from the chemotherapy segment will accrue significant gains through 2032. Based on end-user, the lung cancer treatment market from the specialty clinics segment will observe appreciable growth over 2023-2032.

Non-Small Cell Lung Cancer Treatment in India | Healing Touristry

Healing Touristry 2019-06-28

Non-Small Cell Lung Cancer (NSCLC) Treatment in India.

Lung cancers are one of the most widely recognised cancers around the world.

This cancer is classified as either small cell lung disease (SCLC) or non-small cell lung cancer (NSCLC).

Extensive Stage Small Cell Lung Cancer Market Trend, Growth Opportunities And Forecast TO 2032

bisresearch reports 2022-12-07

Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased. , and• Region is the other segment which covers the seven major markets (the U. Key Companies Profiled• F. Hoffmann-La Roche Ltd• AstraZeneca PLC• Jazz Pharmaceuticals Plc• G1 Therapeutics Inc. Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer.

Extensive Stage Small Cell Lung Cancer Market Report - Focuses on Epidemiology, Product, and Region - BIS Research

Tanzeel Obaid 2023-02-20

The treatment of extensive stage small cell lung cancer has been extremely challenging owing to the poor survival rate of the patients. The Growing Prevalence of Extensive Stage Small Cell Lung CnacerThe prevalence of Extensive Stage Small Lung Cancer is estimated to increase in five of the seven major markets included in the study. Since the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased. , and• Region is the other segment which covers the seven major markets (the U. Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer.

Non-small Cell Lung Cancer Treatment has been discovered to be a short-term cure for NSCLC, with a 5-year survival rate.

CMI Blogging 2021-09-30

Non-small cell lung cancer (NSCLC) is a life-threatening disease that requires prompt attention and treatment.

If this form of cancer is discovered at an early stage, it can be treated using a variety of treatments.

However, if left untreated, it can cause significant harm to the body's other organs.

This cancer is one of the most often diagnosed, as well as one of the most lethal.

As a result, when one learns about a person being affected by this type of cancer, the first thing that comes to mind is the cancer therapy.In reality, the body as a whole is a complicated system.

Detection is mostly accomplished by a series of tests that allow doctors to determine if a certain kind of cancer is present in the patient.

Overview of EGFR Mutations in Non-Small Cell Lung Cancer

MrMed Pharmacy 2023-10-06

The non-small cell lung cancer (NSCLC) is the most prevalent and challenging kind of cancer in the world. In healthy cells, EGFR activation is tightly controlled; however, in NSCLC, EGFR gene alterations can interfere with this control. Exons 18 to 21 of the EGFR gene are frequently affected by EGFR mutations, which are genetic alterations. Non-Smokers and Light Smokers: Individualised lung cancer treatment is crucial since EGFR mutations are more prevalent in non-smokers and light smokers. ConclusionThe existence of EGFR mutations is crucial for determining the diagnosis and course of treatment for Non-Small Cell Lung Cancer.

Molecular Imaging Technology to Detect Lung Cancer

PET Scan Mumbai 2019-09-09

Lung cancer is a common type of cancer that affects both men and women and for which the prognosis is not very good. More people die of lung cancer annually than of any other types of cancers that affect the prostate, breast, and colon combined.

The reason for this is that lung cancers are detected almost always only at an advanced stage of the disease. Moreover, lung cancers are not easily curable. Thanks to improved technologies, doctors of today use molecular imaging studies to screen those at high risk of contracting this disease. This helps to lower the mortality rates.

Molecular Imaging for Detection of Lung Cancer

PET Scans (Positron emission tomography) and CT scans are commonly used screening methods in the Best Lung Cancer Screening Hospitals in Mumbai for detection and further treatment of non-small cell lung cancer. Once the scanning of the patient is completed using these methods, the concerned radiologist would share results with the patient’s specialist physician. NSCLC patients may need to have more than one PET-CT scan depending on the treatment course. These may also include whole-body scans.

Method of using PET-CT studies

The PET and PET-CT screening studies for cancer are used to:

Determine the exact position of the tumor and determine the stage of cancer, i.e., the amount to which cancer has spread in the patient’s body.

Depending on the diagnosis, the genetic makeup of the patient and the molecular structure of the cancer present, select the most potent and suitable therapy.

Determine the effectiveness of the treatment by noting the patient’s response to drug therapy. The changes in the activities at the cellular levels as observed in PET-Ct images, the treatment plans may be altered.

Determine whether cancer has relapsed.

PET-CT Scans – advantages for patients with lung cancer

PET-CT scanning is part of Lung Cancer tests in Mumbai and may be the best method yet to detect whether the cancer cells are actually being destroyed with the ongoing treatment, if the cancer is spreading and whether there has a been a relapse after other forms of treatment.

PET-CT scans help to determine if the (NSCLC) cancer has spread to lymph nodes and can be used in a non-invasive manner to find out the spread of the cancer cells to the lymph nodes instead of a surgical procedure called mediastinoscopy. The tissue cells are collected from the chest cavity and examined under the microscope. The PET_CT scan is in this case used to identify those lymph nodes that may contain cancer cells.

PET-CT scans very accurately determine whether a lung mass is cancerous and can help to avoid surgical biopsy.

Studies have indicated that these types of molecular imaging aids have helped to alter the treatment course for about 64% of lung cancer patients.

Some other ongoing studies and research have pointed out to the fact that the amount of FDG radiotracer absorbed by the cancer cells during a PET scan and survival rate of the patient are related. If the cancer cells absorb less FDG, the survival rate is higher.

Molecular Imaging Studies and Lung Cancer – The Future

Recent studies about the genetic and molecular mechanisms and their connection with the development of lung cancer have seen exciting developments including development of reporter-gene detection systems using imaging where genes are engineered to adhere to other cells and they are further tacked using imaging studies. Moreover, scientists are trying to image molecular markers and biological pathways that may provide clues about the progression of lung cancer and response to therapy in patients.